-
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
•
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical study for its in-house developed gene therapy FT-002. This marks a significant milestone in the development of treatments for X-linked retinitis pigmentosa (XLRP), a genetic disorder affecting vision. FT-002: First-in-Class Gene TherapyFT-002 is a recombinant…
-
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug Designation (ODD) from the US FDA for its Category 1 drug candidate KH617 in glioblastoma. This designation is a significant milestone in the development of KH617, which is aimed at treating advanced solid tumors and…
-
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
•
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase I clinical study for its Category 1 product BA2101. This marks it as the first long-acting anti-IL-4Rα monoclonal antibody to enter the clinical trial stage in China. BA2101 is being developed to treat allergic diseases…
-
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
•
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047, a potential first-in-class small-molecule degrader targeting BRD4, by Hangzhou-based Ranok Therapeutics Co., Ltd, has been accepted for review. This marks a significant step forward in the development of innovative cancer treatments. Discovery and Mechanism of…
-
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences Inc., (NASDAQ: CHRS) have announced positive findings from the final analysis of overall survival (OS) in the pivotal Phase III JUPITER-02 (NCT03581786) clinical study. The study assessed the programmed death-1 inhibitor Tuoyi (toripalimab) as a…
-
Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics
•
US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based Formosa Pharmaceuticals Inc., (TPE: 6838). The partnership aims to combine Eyenovia’s Optejet dispensing technology with Formosa’s unique APNT nanoparticle formulation platform, potentially leading to the development of new topical ophthalmic therapeutics that employ the Optejet…
-
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to carry out an open, multi-center Phase Ib/II clinical study for its injectable pipeline candidate SHR-A1921 combined with adebrelimab (SHR-1316) in advanced solid tumors. This marks a significant step in the development of…
-
Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first clinical treatment of an atrial fibrillation patient using its first-in-class HeartLight X3 laser ablation platform. The procedure was carried out at the Hainan branch of Shanghai’s Ruijin Hospital, marking a significant milestone in the company’s…
-
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for its Category 1 product candidates ZG2001 and ZG0895 have both been accepted for review by the National Medical Products Administration (NMPA) in China. This marks a significant milestone in the development of these innovative drug…
-
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
•
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase II clinical study for its IBI311, a recombinant anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in thyroid-associated ophthalmopathy (TAO). IBI311 is an IGF-1R-targeting monoclonal antibody independently developed by Innovent, marking a significant step in the…
-
Hygea Medtech Secures Series D Funding for Oncology Device Expansion
•
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based in Beijing, has reportedly raised “hundreds of millions” of renminbi in a Series D financing round. This significant funding round was led by In Capital, with contributions from Banyan Pacific Capital, Huajin Capital, Qiandao Investment…
-
CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research
•
China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services provider, has announced the 100% acquisition of compatriot firm Vectoring Pharmatech Ltd. This strategic move is designed to enhance CTI’s business layout in the pharmacy CMC (Chemistry, Manufacturing, and Controls) research field. No financial details…
-
Shenzhen United Family Hospital Partners with GBA Medical Delegation
•
Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), aimed at accelerating high-quality healthcare development and medical exchanges in the region. This collaboration is a significant step towards enhancing the healthcare ecosystem in the GBA. Shenzhen United Family Hospital:…
-
Vincentage Raises RMB 100 Million for Innovative Drug Development
•
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6 million) in its latest financing round. This significant funding will be used to accelerate clinical studies and regulatory filings for multiple innovative drugs, particularly oral small molecule GLP-1RA drugs, as well as to develop new…
-
Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences Co., Ltd, a Beijing-based biotech specializing in applying bioinformatics, genomics, and cutting-edge internet technologies to clinical medicine and personal health, have signed a long-term collaboration agreement. The partnership aims to integrate short-read sequencing and long-read…
-
Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC
•
Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made another initial public offering (IPO) filing with the Hong Kong Stock Exchange, sponsored by CICC. This marks the company’s second attempt at going public on the bourse, following the failure of its first IPO attempt…
-
Mindray Launches First Wireless Handheld Ultrasound System, TE Air
•
China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s first wireless handheld ultrasound system, branded TE Air. This innovative device represents a historic breakthrough in image quality, integrating professional-level imaging into a compact and lightweight wireless system for ease of use in various medical…
-
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced a licensing agreement with US firm Cullinan Oncology, Inc. The deal grants Cullinan exclusive rights to develop and commercialize HBM7008 in the United States (including the District of Columbia and Puerto Rico). This…
-
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
•
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment in a Phase I clinical study for its tetravalent influenza virus split vaccine. This marks a significant step in the development of a vaccine designed to provide broader protection against influenza, particularly for individuals aged…
